PA8541101A1 - Compuestos farmaceuticamente activos - Google Patents
Compuestos farmaceuticamente activosInfo
- Publication number
- PA8541101A1 PA8541101A1 PA20028541101A PA8541101A PA8541101A1 PA 8541101 A1 PA8541101 A1 PA 8541101A1 PA 20028541101 A PA20028541101 A PA 20028541101A PA 8541101 A PA8541101 A PA 8541101A PA 8541101 A1 PA8541101 A1 PA 8541101A1
- Authority
- PA
- Panama
- Prior art keywords
- active compounds
- pharmaceutically active
- phosphodesterase
- profilactic
- heteroarilo
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 abstract 2
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 abstract 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 abstract 1
- 101100189582 Dictyostelium discoideum pdeD gene Proteins 0.000 abstract 1
- 101150098694 PDE5A gene Proteins 0.000 abstract 1
- 102100029175 cGMP-specific 3',5'-cyclic phosphodiesterase Human genes 0.000 abstract 1
- 239000002131 composite material Substances 0.000 abstract 1
- 229940029575 guanosine Drugs 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 150000004712 monophosphates Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Reproductive Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Endocrinology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
SE PROPORCIONA UN COMPUESTO DE FORMULA GENERAL I: O UNA SAL FARMACEUTICA O VETERINARIAMENTE ACEPTABLE O POLIMORFO Y/O SOLVATO DEL MISMO, EN LA QUE R1 REPRESENTA H; C(O)ALQUILO C1-C4; C(O)ARILO; O C(O)HETEROARILO; Y QUE ES UTIL EN EL TRATAMIENTO CURATIVO Y PROFILACTICO DE UNA AFECCION MEDICA PARA LA QUE SE DESEA LA INHIBICION DE LA GUANOSINA 3´, 5´- MONOFOSFATO CICLICO FOSFODIESTERASA (Y, EN PARTICULAR, GMPC PDE5).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0105893.2A GB0105893D0 (en) | 2001-03-09 | 2001-03-09 | Pharmaceutically active compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PA8541101A1 true PA8541101A1 (es) | 2003-11-12 |
Family
ID=9910362
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PA20028541101A PA8541101A1 (es) | 2001-03-09 | 2002-03-08 | Compuestos farmaceuticamente activos |
Country Status (8)
| Country | Link |
|---|---|
| AP (1) | AP2002002462A0 (es) |
| GB (1) | GB0105893D0 (es) |
| GT (1) | GT200200044A (es) |
| HN (1) | HN2002000050A (es) |
| PA (1) | PA8541101A1 (es) |
| PE (1) | PE20021153A1 (es) |
| TN (1) | TNSN02023A1 (es) |
| WO (1) | WO2002072586A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10675280B2 (en) | 2001-10-20 | 2020-06-09 | Sprout Pharmaceuticals, Inc. | Treating sexual desire disorders with flibanserin |
| UA78974C2 (en) | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
| DE60332387D1 (de) | 2002-12-13 | 2010-06-10 | Warner Lambert Co | Alpha-2-delta-ligand zur behandlung vonsymptomen der unteren harnwege |
| WO2005007166A1 (en) * | 2003-07-16 | 2005-01-27 | Pfizer Limited | Treatment of sexual dysfunction |
| PL1912650T3 (pl) | 2005-08-03 | 2018-01-31 | Sprout Pharmaceuticals Inc | Zastosowanie flibanseryny w leczeniu otyłości |
| CA2626134C (en) | 2005-10-29 | 2013-12-24 | Boehringer Ingelheim International Gmbh | Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders |
| EP2037927B1 (en) | 2006-06-30 | 2010-01-27 | Boehringer Ingelheim International GmbH | Flibanserin for the treatment of urinary incontinence and related diseases |
| AR062320A1 (es) | 2006-08-14 | 2008-10-29 | Boehringer Ingelheim Int | Formulaciones de flibanserina y metodo para fabricarlas |
| WO2008022932A2 (en) | 2006-08-25 | 2008-02-28 | Boehringer Ingelheim International Gmbh | Controlled release system and method for manufacturing the same |
| CL2008002693A1 (es) | 2007-09-12 | 2009-10-16 | Boehringer Ingelheim Int | Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad |
| CA2686480A1 (en) | 2008-12-15 | 2010-06-15 | Boehringer Ingelheim International Gmbh | New salts |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR200003039T2 (tr) * | 1998-04-20 | 2001-01-22 | Pfizer Inc. | Seksüel fonksiyon bozukluklarının tedavisi için pirazolopirimidinon cGMP PDE5 inhibitörleri |
| GB9823101D0 (en) * | 1998-10-23 | 1998-12-16 | Pfizer Ltd | Pharmaceutically active compounds |
| EA200200240A1 (ru) * | 1999-10-11 | 2002-10-31 | Пфайзер Инк. | 5-(2-ЗАМЕЩЕННЫЕ-5-ГЕТЕРОЦИКЛИЛСУЛЬФОНИЛПИРИД-3-ИЛ)-ДИГИДРОПИРАЗОЛО[4,3-d]ПИРИМИДИН-7-ОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ФОСФОДИЭСТЕРАЗЫ |
| CO5271697A1 (es) * | 2000-01-12 | 2003-04-30 | Pfizer Prod Inc | Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona |
-
2001
- 2001-03-09 GB GBGB0105893.2A patent/GB0105893D0/en not_active Ceased
-
2002
- 2002-02-27 WO PCT/IB2002/000622 patent/WO2002072586A1/en not_active Ceased
- 2002-03-06 GT GT200200044A patent/GT200200044A/es unknown
- 2002-03-07 PE PE2002000183A patent/PE20021153A1/es not_active Application Discontinuation
- 2002-03-07 AP APAP/P/2002/002462A patent/AP2002002462A0/en unknown
- 2002-03-08 PA PA20028541101A patent/PA8541101A1/es unknown
- 2002-03-08 HN HN2002000050A patent/HN2002000050A/es unknown
- 2002-03-08 TN TNTNSN02023A patent/TNSN02023A1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GB0105893D0 (en) | 2001-04-25 |
| AP2002002462A0 (en) | 2002-06-30 |
| WO2002072586A1 (en) | 2002-09-19 |
| PE20021153A1 (es) | 2002-12-17 |
| GT200200044A (es) | 2002-12-02 |
| HN2002000050A (es) | 2002-09-13 |
| TNSN02023A1 (fr) | 2005-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20060981L (no) | Pyridazinderivater og deres anvendelse som terapeutiske midler | |
| BR0004786A (pt) | Compostos farmaceuticamente ativos | |
| AR022665A1 (es) | Compuestos farmaceuticamente activos | |
| CY1110690T1 (el) | Ενωσεις 4-οξοκινολινης και χρησιμοποιηση αυτων ως αναστολεις της ενσωματασης του hiv | |
| NO20074619L (no) | Spiro-oksindolforbindelser og deres anvendelse som medikamenter | |
| GT200000171A (es) | Compuestos farmaceuticamente activos. | |
| BR0004779A (pt) | Compostos farmaceuticamente ativos | |
| TW200615266A (en) | Organic compounds | |
| PA8541101A1 (es) | Compuestos farmaceuticamente activos | |
| ECSP055701A (es) | Nuevos derivados de pirimidinamida y el uso de los mismos | |
| SE9901573D0 (sv) | New compounds | |
| BR9807950A (pt) | Composto, composição farmacêutica, uso de um composto, e, processos para tratar ou reduzir o risco de doenças ou condições humanas, o risco de doença inflamatória o risco da dor e para a preparação de um composto | |
| AR043259A1 (es) | Metodo para el tratamiento de insuficiencia cardiaca severa y medicamento para ello | |
| ES2139673T3 (es) | Utilizacion de norastemizol para el tratamiento de rinitis alergica. | |
| NO20060146L (no) | Benzimidazolderivater, sammensetninger som inneholder slike, fremstilling derav og anvendelse derav | |
| BR0208463A (pt) | Compostos farmaceuticamente ativos | |
| SE0201837D0 (sv) | Chemical compounds | |
| DK1213289T3 (da) | N-benzensulfonyl-L-prolinforbindelser som bradykininantagonister | |
| PE20040706A1 (es) | Derivado especifico de amina ciclica y sus sales farmaceuticamente aceptables involucrados en la prevencion de la insuficiencia cardiaca | |
| SE9901572D0 (sv) | New compounds | |
| ES2247060T3 (es) | Producto que comprende un inhibidor de la transduccion de las señales de las proteinas g heterotrimericas en asociacion con un agente antihipertensor para una utilizacion terapeutica en el tratamiento de la hipertension arterial. | |
| EA201991188A1 (ru) | Новые ингибиторы глутаминилциклаз и их применение для лечения различных заболеваний | |
| NO20081736L (no) | Antitumormidler | |
| DOP2002000354A (es) | Compuestos farmaceuticamente activos. | |
| SE0103272D0 (sv) | Chemical compounds |